CMS comment deadline arrives for sweeping 2027 Medicare proposal
CMS comments close September 14 on a proposed 2027 Medicare rule covering physician payments, telehealth, rural care, drug rebates and eligibility.
CMS comments close September 14 on a proposed 2027 Medicare rule covering physician payments, telehealth, rural care, drug rebates and eligibility.
Medicare plans send September notices before Open Enrollment. Here are the costs, doctors, pharmacies and prescriptions beneficiaries should check for 2027.
Dompé will pay $32 million plus interest to resolve DOJ allegations involving foundation-funded Medicare co-pays for its Oxervate eye treatment.
CMS has released preliminary 2027 Part D figures, but plan premiums, drug lists and networks remain pending before Medicare open enrollment begins Oct. 15.
CMS is starting a national process that may shorten routine surveys for about 12% of nursing homes while preserving complaint investigations and safety oversight.
FinCEN says bank reports flagged $17.5 billion in suspicious health care activity, but the figure is not a confirmed fraud or taxpayer-loss total.
CMS says it stopped more than $1.6 billion in potentially improper Medicare lab payments through revocations, suspensions, referrals and recoveries.
CMS’s ACCESS model adds a participant start date on August 17, but availability, costs and results still depend on providers, location and track.
Northern Louisiana Medical Center reduced its alleged deficiencies from 24 to 14 in a July follow-up, but regulators had not publicly confirmed full compliance 16 days before the hospital’s stated August 30 Medicare deadline.
The proposed rule covers 2027 Medicare payments for hospital outpatient departments and ambulatory surgical centers, as well as quality reporting, star ratings and hospital price transparency.
Access DX Laboratory, former CEO Michael Stewart and Florida businessman Harold Shatz reached settlements with the United States over alleged kickbacks and medically unnecessary genetic testing billed to Medicare and Medicaid.
A new CMS demonstration began July 1, 2026, offering eligible Medicare Part D beneficiaries certain GLP-1 medications for $50 per monthly supply through the end of 2027.
CMS proposed long-term rules for negotiating and renegotiating prices for high-cost, single-source Medicare drugs beginning in 2029. Comments are due Aug. 17, 2026.
The proposed changes would affect Medicare payments to hospital outpatient departments and ambulatory surgical centers beginning in calendar year 2027, but rates are not final.
A new federal trustees summary projects that combined Social Security and Medicare costs will rise from about 5.3% of GDP in 2026 to approximately 6.9% in 2084 before easing to about 6.7%.
The proposed changes would make accountable-care organizations easier to join and shift clinicians away from traditional MIPS reporting. Comments are due Sept. 14, 2026.
CBO projects $33.6 trillion in federal health insurance subsidies through 2036, while the uninsured population rises from 30 million to 37 million.
CMS proposes broader Medicare enrollment enforcement and a projected 2.4% aggregate home-health payment increase for 2027. Comments are due August 31.
CMS’s temporary Medicare GLP-1 Bridge offers selected beneficiaries a $50 monthly route to certain weight-loss drugs, but strict eligibility limits apply.
CMS will begin shorter routine surveys for some high-performing nursing homes on September 8, but complaints and safety concerns can still trigger traditional inspections.
CMS’s proposed 2027 Medicare rule could lower some outpatient costs while changing payments for hospitals, surgery centers and 340B drugs.
CMS will end a temporary Medicare Part D premium stabilization program after 2026. Some seniors could pay more in 2027, but final plan prices come in September.